Browse the evidence

Leucine acts as the primary trigger for muscle protein synthesis by activating the mTORC1 pathway, and increasing leucine content in lower-quality proteins can restore the anabolic response in older adults.

Ensure your meals contain enough leucine, the 'trigger' for muscle building. High-quality proteins like whey, eggs, and meat are naturally rich in leucine. If you rely on plant proteins or lower-quality sources, you may need to consume larger portions or combine them to get enough leucine, especially as you age.

Bariatric surgery leads to greater improvements in lipid profiles (increased HDL, decreased triglycerides) compared to non-surgical treatment, while LDL and total cholesterol changes are not significantly different.

Bariatric surgery improves lipid profiles by significantly increasing HDL ('good') cholesterol and decreasing Triglycerides compared to medical management. While LDL cholesterol may not change significantly, the overall improvement in lipid markers contributes to reduced cardiovascular risk. Patients should view lipid improvement as one of the key benefits of surgery alongside glycemic control.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) reduce systemic and tissue inflammation through mechanisms that are partially independent of weight loss and metabolic improvements.

GLP-1 medications like semaglutide and liraglutide offer health benefits beyond just weight loss. They directly reduce inflammation in your body, which helps protect your heart, kidneys, and joints. This happens through direct actions on your immune system and nerves, not just by making you thinner. Even if your weight stays the same, you may still receive these protective anti-inflammatory effects.

Home-based training (HBT) is a viable alternative to supervised exercise training (SET) when SET is not feasible, provided it is structured and monitored.

If you can't go to a supervised program, start a home-based walking plan. Walk 3 times a week, starting with 20 minutes and building up to 60. Use a pedometer or smartwatch to track your activity, and consider logging your pain levels. This is just as effective as supervised exercise if you monitor yourself.

A 3-year worksite lifestyle intervention significantly improves cardiovascular health metrics in middle-aged adults, but the effect attenuates to non-significance after the first year when intervention intensity is reduced.

If you are implementing a lifestyle change for heart health, expect significant benefits in the first year if you engage actively with coaching and tracking tools. However, do not assume these benefits will persist automatically if you stop engaging with the program after the first year. To maintain gains, you must either continue with periodic check-ins or independently maintain the high level of behavioral effort established during the initial intensive phase.

A lifestyle intervention is effective in improving cardiovascular health metrics in individuals with low baseline subclinical atherosclerosis, but ineffective in those with high baseline subclinical atherosclerosis.

If you have significant underlying cardiovascular disease (high subclinical atherosclerosis), standard lifestyle advice (diet, exercise, no smoking) may not be enough to improve your health metrics. You likely need more intensive, specialized medical or behavioral interventions. Do not assume that standard lifestyle changes will yield the same results as they do for healthier individuals.

Adherence to low-carbohydrate (LCD) and very low-carbohydrate ketogenic diets (VLCKD) is significantly lower than adherence to vegan or vegetarian diets, with attrition rates often exceeding 40-60% in long-term trials, leading to a convergence of metabolic outcomes between diet groups over time.

If you are trying a low-carb or keto diet for diabetes or weight loss, expect that sticking to it is the hardest part. Many people drop out or stop strictly following the diet within a year, causing their results to look like those of people on other diets. To succeed, focus on sustainability over perfection. If strict keto (<50g carbs) feels too restrictive or socially isolating, a moderate low-carb approach (<130g carbs) might be easier to maintain long-term, even if the initial weight loss is slower. The key is not the specific number of grams, but your ability to keep the diet going.

Medication reduction is a prominent and immediate benefit of VLCKD, often occurring before significant weight loss or A1c improvement is sustained, and may blunt the observed A1c response in long-term studies.

If you have Type 2 Diabetes, starting a very low-carb diet (<50g carbs/day) often leads to a rapid need to reduce or stop diabetes medications, sometimes before you lose much weight. This is a good thing, but it requires close monitoring by your doctor to avoid hypoglycemia. Do not stop your medications on your own; work with your provider to adjust doses as your blood sugar improves.

GLP1/Estrogen (GLP1/E) multi-agonist therapy provides superior metabolic improvement in PCOS models compared to GLP1 monotherapy, dual/triple agonists, and metformin, achieving significant weight loss, fat mass reduction, and improved insulin sensitivity without gastrointestinal distress.

For individuals with PCOS and metabolic issues, GLP1/Estrogen multi-agonist therapy appears to be a highly effective treatment option, significantly outperforming standard care like metformin in reducing weight, fat, and improving insulin sensitivity. While currently studied in mice, this suggests a promising future therapeutic avenue for managing PCOS-related metabolic complications.

Adherence to a Mediterranean diet significantly reduces the incidence of peripheral artery disease (PAD) and improves claudication symptoms through oxidative stress reduction and anti-inflammatory effects.

Adopt a Mediterranean-style eating pattern: use olive oil as your primary cooking fat, eat plenty of vegetables, fruits, legumes, and whole grains, include moderate amounts of fish and dairy, and limit red and processed meats. This approach has been shown to significantly reduce the risk of developing peripheral artery disease and improve walking symptoms in those who already have it.

Intentional weight loss of >5 pounds in patients with intermittent claudication reduces the annual decline in walking distance, independent of muscle loss.

If you have PAD and are overweight, aim to lose more than 5 pounds. This specific amount of weight loss has been shown to help you walk further for longer, even if you lose some leg muscle in the process. Combine this with exercise for best results.

GLP-1 receptor agonists (GLP-1RAs) including semaglutide 2.4 mg and tirzepatide induce significant weight loss (12-20%) and improve metabolic comorbidities, but discontinuation of therapy leads to rapid weight regain, indicating that obesity treatment with these agents requires long-term or lifelong administration.

GLP-1 medications like semaglutide (2.4 mg weekly) and tirzepatide are highly effective for weight loss, achieving 12-20% body weight reduction in clinical trials. However, these drugs treat obesity as a chronic condition; stopping treatment typically leads to rapid weight regain. Therefore, successful long-term management likely requires continuous, lifelong therapy. Side effects like nausea are common but manageable through slow dose escalation. Oral versions are emerging to address injection aversion.

Higher habitual dairy intake causally increases lean body mass in adults, as evidenced by Mendelian randomization analysis of 182,041 individuals.

To support lean mass maintenance or growth, include dairy in your daily diet. The study suggests a causal link between higher dairy intake and increased lean mass. Aim for multiple servings per day if tolerated, as the benefit appears dose-dependent.

Body composition assessment (quantifying fat-free mass, fat mass, and visceral adipose tissue) provides a more accurate assessment of cardiometabolic disease risk than Body Mass Index (BMI) alone, particularly for identifying 'normal weight obesity' and sarcopenic obesity.

Stop relying solely on the scale. If you are maintaining a 'normal' BMI but feel weak or have high blood sugar, ask for a body composition assessment (like DXA or BIA). This will reveal if you have 'normal weight obesity' (high fat, low muscle) or sarcopenic obesity (high fat, low muscle), which are high-risk conditions that BMI misses. Prioritize resistance training and protein intake to build muscle, as this is the most effective way to lower metabolic risk when BMI is misleading.

Visceral Adipose Tissue (VAT) is a stronger predictor of metabolic syndrome and cardiovascular disease risk than total fat mass or BMI, particularly in Asian populations where VAT accumulation occurs at lower BMI thresholds.

Focus on reducing visceral fat, not just total weight. If you are Asian or older, your BMI might be 'normal' while your visceral fat is high. Use waist circumference or body composition scans to monitor VAT. Reducing VAT through exercise and diet is critical for lowering metabolic syndrome risk.

Psychogenic factors, particularly stress and PTSD, are decisive in the development of obesity through mechanisms involving high cortisol and sympathetic overactivity.

If you struggle with stress or PTSD, recognize that these mental health challenges can biologically drive weight gain through cortisol. Addressing mental health through therapy or stress management is a critical part of obesity treatment.

Epigenetic interventions, pharmacotherapy, and bariatric surgery are emerging as important tools for obesity management, alongside lifestyle changes.

Consult with a healthcare provider about advanced treatment options like pharmacotherapy or bariatric surgery if lifestyle changes alone are insufficient. These are valid medical tools, not last resorts.

Bariatric surgery (gastric bypass, sleeve gastrectomy, or adjustable gastric banding) is cost-effective over a 10-year horizon and cost-saving over a lifetime compared to conventional medical management, primarily by reducing the incidence of type 2 diabetes and cardiovascular events.

For obese individuals with BMI >40 (or >35 with Type 2 Diabetes) who have failed conservative weight loss, bariatric surgery is a clinically and economically superior long-term strategy compared to medical management alone. It significantly reduces the risk of diabetes and cardiovascular disease, leading to cost savings and improved quality of life over a lifetime. However, access barriers like insurance restrictions and waiting lists should be minimized, as delays result in lost health benefits.

Equating total training volume, resistance training performed 2 days per week produces similar increases in muscular strength and hypertrophy compared to 3 days per week in resistance-trained men.

If you are an experienced lifter, you do not need to train every muscle group 3+ times a week to maximize gains. As long as you are hitting the same total number of hard sets per week, splitting those sets across 2 days (e.g., Upper/Lower or Push/Pull/Legs) works just as well as hitting them 3 times. Focus on getting your total weekly volume in, rather than obsessing over high frequency.

High baseline insulin secretion predicts greater long-term weight gain, particularly when consuming high-glycemic-index diets, supporting the carbohydrate-insulin model of obesity pathogenesis.

If you have high insulin levels, focus on reducing the glycemic load of your diet. High-glycemic foods may trigger excessive insulin secretion, promoting fat storage and weight gain, especially in those predisposed to insulin resistance.

Increased gut microbiome diversity and high dietary fiber intake are associated with lower long-term weight gain, mediated by short-chain fatty acids (SCFAs) like butyrate.

Increase your intake of dietary fiber to promote a diverse gut microbiome. This can lead to higher levels of beneficial SCFAs like butyrate, which improve insulin sensitivity and may help prevent long-term weight gain.

In overweight and obese women, twice-daily exenatide treatment yields long-term weight loss outcomes similar to a hypocaloric diet with matched placebo injections, with no significant difference in the proportion of super responders (≥10% weight loss).

For overweight women, twice-daily exenatide does not guarantee better long-term weight loss than a strict hypocaloric diet alone. In fact, the study showed similar rates of significant weight loss (≥10%) between the drug and diet groups. The high response in the diet group suggests that the ritual of pre-meal injections may aid adherence. Patients should weigh the burden of daily injections against the potential benefit, as diet alone can be highly effective for early responders.

Ultraprocessed food (UPF) consumption is positively associated with body fat percentage, independent of energy expenditure, age, sex, and economic development rank.

If you are trying to manage body fat, the type of food matters as much as the amount. Ultraprocessed foods are linked to higher body fat even when you account for how much you move. Prioritize whole, minimally processed foods to improve satiety and potentially reduce net energy absorption.

Functional and physiological biomarkers are more suitable for medium- and long-term interventions (≥3 months) than acute or short-term interventions (<3 months).

If you are designing an intervention study to measure aging, ensure the intervention lasts at least 3 months (medium) or 6 months (long). Short-term interventions are unlikely to yield meaningful changes in these biomarkers.